Laborie Secures New AMA CPT Code for Advanced Prostate Procedure

Laborie Medical Technologies Corp (Laborie), a top company in diagnostic and therapeutic medical technology, disclosed that the American Medical Association (AMA) has introduced the new Category 1 Current Procedural Terminology (CPT) code 52XX2 for documenting cystourethroscopy, along with initial transurethral anterior prostate commissurotomy.

The fresh code applies to services carried out by doctors using Laborie’s Optilume BPH Catheter System, a minimally invasive surgical therapy (MIST) that involves mechanical dilation using a unique double-lobe balloon along with simultaneous localized administration of paclitaxel for the treatment of lower urinary tract symptoms (LUTS) caused by BPH.

Optilume BPH sets a new standard in treating BPH-induced LUTS with the highest Qmax recorded in BPH MIST clinical trials to date (19mL/sec at 2 years), offering immediate and long-lasting symptom relief and minimal recovery time for men. The technology was created to address the dissatisfaction patients and doctors have with existing treatment choices.

“This is a significant milestone for Optilume BPH, and we welcome the AMA Editorial Panel’s decision,” said Michael Frazzette, Laborie’s President and CEO. “The new code will broaden patient access by establishing a reimbursement pathway for this important treatment and will help enable adoption at various sites of care.”

Starting from January 1, 2026, healthcare professionals have the option to record the updated CPT code for Optilume BPH. Developed and upheld by the AMA, CPT codes are commonly utilized to depict medical services and procedures for easier reimbursement by both public and private health insurance companies in the United States.